The stroke therapeutics market share is expected to increase by USD 1.54 billion from 2020 to 2025, and the market’s growth momentum will accelerate at a CAGR of 5.00%.
This stroke therapeutics market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers stroke therapeutics market segmentation by type (ischemic stroke and hemorrhagic stroke) and geography (North America, Europe, Asia, and ROW). The stroke therapeutics market report also offers information on several market vendors, including Amgen Inc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Johnson and Johnson Inc., Merck and Co. Inc., Pfizer Inc., and Sanofi SA among others.
What will the Stroke Therapeutics Market Size be During the Forecast Period?
Download the Free Report Sample to Unlock the Stroke Therapeutics Market Size for the Forecast Period and Other Important Statistics
Stroke Therapeutics Market: Key Drivers, Trends, and Challenges
The high-risk factors for stroke is notably driving the stroke therapeutics market growth, although factors such as high level of genericization in the market may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the stroke therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Stroke Therapeutics Market Driver
One of the key factors driving growth in the stroke therapeutics market is the high-risk factors for stroke. Stroke is the second-leading cause of death globally among adults. Strokes are responsible for two-thirds of deaths among people living in developing countries. The high prevalence of stroke is mainly attributed to the increase in the incidence of ischemic strokes and hemorrhagic strokes, mainly because of the increasing presence of high-risk factors over the years. The increase in the risk factors for strokes is one of the major drivers for the growth of the market. The major risk factors are high blood pressure, high cholesterol levels and obesity, heart diseases, diabetes, sickle cell disease, smoking, and excessive alcohol consumption. The presence of high-risk factors for stroke is expected to increase its prevalence globally, thereby driving the market growth during the forecast period.
Key Stroke Therapeutics Market Trend
The development of novel therapies is another factor supporting the stroke therapeutics market share growth. The global stroke therapeutics market is expected to benefit from the development of novel therapies, such as stem cell therapies. Owing to the high prevalence of stroke, there is a huge need for safe and innovative novel therapies to treat stroke. Therefore, several companies are developing novel drugs for the treatment of stroke. The development of stem cell therapy will have a major impact on upcoming stroke therapeutics, as it has fewer side effects and regenerative properties. For instance, Athersys is developing MultiStem. It is a cell therapy regenerative medicine product currently in Phase III clinical development for the treatment of ischemic strokes. MultiStem has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors produced in response to signals of inflammation and tissue damage. The development of such novel therapies with fewer side effects is expected to contribute to market growth during the forecast period.
Key Stroke Therapeutics Market Challenge
The high level of genericization in the market will be a major challenge for the stroke therapeutics market during the forecast period. Owing to the patent expiry of several branded drugs, pharmaceutical companies have entered the market with low-cost generics, which have affected the sales of high-cost branded drugs. For instance, after CRESTOR (rosuvastatin calcium from AstraZeneca) lost its patent exclusivity, several companies received approvals for generic versions of the drug. In May 2019, Shandong Bechem Chemicals Co. Ltd. received an abbreviated new drug application (ANDA) approval for generic rosuvastatin calcium. Moreover, tentative approvals for and market entry of the generic versions of many branded products are expected after their patent expiry. The growing dominance of low-cost generics is expected to hamper the growth of the market during the forecast period by affecting the sales of, and consequently, the revenue from high-cost branded drugs.
This stroke therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.
Parent Market Analysis
Technavio categorizes the global stroke therapeutics market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the stroke therapeutics market during the forecast period.
Who are the Major Stroke Therapeutics Market Vendors?
The report analyzes the market’s competitive landscape and offers information on several market vendors, including:
- Amgen Inc.
- AstraZeneca Plc
- Bayer AG
- Boehringer Ingelheim International GmbH
- Bristol Myers Squibb Co.
- F. Hoffmann La Roche Ltd.
- Johnson and Johnson Inc.
- Merck and Co. Inc.
- Pfizer Inc.
- Sanofi SA
This statistical study of the stroke therapeutics market encompasses successful business strategies deployed by the key vendors. The stroke therapeutics market is fragmented and the vendors are deploying growth strategies such as forming strategic alliances and acquisitions to compete in the market.
Product Insights and News
-
Amgen Inc. - The company offers stroke therapeutics named Repatha.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The stroke therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Stroke Therapeutics Market Value Chain Analysis
Our report provides extensive information on the value chain analysis for the stroke therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chains is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
The value chain of the pharmaceuticals market includes the following core components:
- Research and development (R&D) and drug discovery
- Integration and product development
- Manufacturing
- Outbound logistics
- Marketing and sales
- Support activities
- Innovation
The report has further elucidated on other innovative approaches being followed by manufacturers to ensure a sustainable market presence.
Which are the Key Regions for Stroke Therapeutics Market?
For more insights on the market share of various regions Request for a FREE sample now!
40% of the market’s growth will originate from North America during the forecast period. The US is the key market for stroke therapeutics in North America. Market growth in this region will be faster than the growth of the market in the European and ROW regions.
The high prevalence of the disease and recent product approvals will facilitate the stroke therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
In 2020, the outbreak of COVID-19 impacted the clinical trials for stroke therapeutics in the region. Due to the outbreak, pharmaceutical companies shifted their focus mainly toward developing COVID-19 medicines and vaccines. However, a stroke is a critical disease that requires constant medications and clinical visits even during the pandemic. Also, since cases of COVID-19 have reduced in 2021, the focus on clinical trials for stroke therapeutics has increased. This will drive the market growth during the forecast period.
What are the Revenue-generating Type Segments in the Stroke Therapeutics Market?
To gain further insights on the market contribution of various segments Request for a FREE sample
The stroke therapeutics market share growth by the ischemic stroke segment will be significant during the forecast period. The growth of this segment is majorly driven by the high prevalence of strokes. High-risk factors, such as obesity, atherosclerosis, hypertension, and old age, are the major contributors to the growth of the segment during the forecast period. The growth of this segment is also expected to be driven by the robust development of the drug pipeline for this type of stroke. Novel therapies, such as MultiStem from Athersys and NA-1 from NoNO Inc. (NoNO), are expected to receive marketing approval. The availability of patient assistance programs for branded drugs by pharmaceutical manufacturers is expected to propel the growth of this segment during the forecast period.
This report provides an accurate prediction of the contribution of all the segments to the growth of the stroke therapeutics market size and actionable market insights on post COVID-19 impact on each segment.
|
Stroke Therapeutics Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2020 |
|
Forecast period |
2021-2025 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 5.00% |
|
Market growth 2021-2025 |
$ 1.54 billion |
|
Market structure |
Fragmented |
|
YoY growth (%) |
4.68 |
|
Regional analysis |
North America, Europe, Asia, and ROW |
|
Performing market contribution |
North America at 40% |
|
Key consumer countries |
US, Germany, UK, China, and Japan |
|
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
|
Key companies profiled |
Amgen Inc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Johnson and Johnson Inc., Merck and Co. Inc., Pfizer Inc., and Sanofi SA |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
What are the Key Data Covered in this Stroke Therapeutics Market Report?
- CAGR of the market during the forecast period 2021-2025
- Detailed information on factors that will drive stroke therapeutics market growth during the next five years
- Precise estimation of the stroke therapeutics market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the stroke therapeutics industry across North America, Europe, Asia, and ROW
- A thorough analysis of the market’s competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of stroke therapeutics market vendors
We can help! Our analysts can customize this report to meet your requirements. Get in touch